Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 16:01 ET
|
Kura Oncology, Inc.
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008...
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
February 26, 2024 07:30 ET
|
Kura Oncology, Inc.
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML – SAN DIEGO, Feb. 26, 2024 (GLOBE...
Kura Oncology to Participate in Three Upcoming Investor Conferences
February 22, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
January 30, 2024 07:00 ET
|
Kura Oncology, Inc.
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML – – 56% CR/CRh with ven/aza in menin inhibitor naïve patients with R/R AML – – 80%...
Kura Oncology Announces Oversubscribed $150 Million Private Placement
January 24, 2024 07:00 ET
|
Kura Oncology, Inc.
– Funding from existing investors, including EcoR1 Capital, an affiliate of Deerfield Management and Suvretta Capital – – Pro forma cash, cash equivalents and investments expected to provide runway...
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
January 17, 2024 16:01 ET
|
Vor Biopharma
First patient dosed in company’s second clinical program with initial data expected in second half of 2024Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass.,...
La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA)
January 16, 2024 13:30 ET
|
Hyloris Pharmaceuticals SA
La FDA Américaine Accorde la Qualification de Médicament Orphelin au PTX-252 pour le Traitement de la Leucémie Myéloïde Aiguë (LMA) Le PTX-252 (précédemment appelé agent plécoïdeTM) est une nouvelle...
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML)
January 16, 2024 13:30 ET
|
Hyloris Pharmaceuticals SA
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of Acute Myeloid Leukaemia (AML) PTX-252 (previously referenced as a Plecoid™Agent) is a novel molecular entity developed in...